AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
34
- +2 vs. Q1 2026
- Total value $357.32M
Superinvestors holding AGMB
0
- None of the superinvestors held AGMB at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by AGMB insiders, newest first.
No open-market purchases or sales by AGMB insiders are on file.
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in AGMB at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | $66.74M | 7.74% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 3,136,376 | $40.71M | 1.23% | +1,936,376+161.4% | Added |
| Sanofi | 2,783,096 | $36.12M | 6.76% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,733,926 | $35.49M | 2.38% | +2,577,676+1,649.7% | Added |
| Cormorant Asset Management, LP | 2,465,348 | $32M | 1.64% | 00.0% | Unchanged |